Opinions
Norman Levine
Astellas Pharma Inc
ALPMY-O
PAST TOP PICK
Nov 27, 2020
(A Top Pick Nov 08/19, Down 7%) All pharmas face a "patent cliff" where they drugs they developed are about to go generic, so companies need to develop new drugs or buy companies. Theirs ended in March. This is going from a value into a growth stock. They now have 3 drugs in the pipeline, including a blader cancer one, a prostate one, and one for severe menopause which has great potential and awaiting approval. The stock hasn't done much, but the potential is high.
N/A
Stock price when the opinion was issued
Pharma & Healthcare
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
TOP PICK
It has been a long time since they have held a Japanese company. They are near the end of their "patent cliff", when the share price is negatively impacted by patent protection ending. They specialize in new cancer drugs and have a lot of new patents coming forward. Japan and healthcare shares are improving. Yield 2.17% (Analysts’ price target is $19.40)
Pharma & Healthcare
Advertising